Bristol Myers' Zola-Cel Pause Sends Partner Oxford BioMedica Down 14.7%
BMY sits 57% above its 52-week low of $42.52 on light trading volume (0.2× avg).
Summary
Bristol Myers Squibb's voluntary pause of its Zola-Cel CAR-T program for autoimmune disorders is now rippling through partners. Oxford BioMedica, which has ties to the program, tumbled 14.7% in London trading. The pause was first reported earlier today; this update adds the market reaction and confirms the impact on a collaborator. The move raises questions about the safety or efficacy signal that triggered the review, though no details have been disclosed. Investors will watch for further updates from the company on the clinical data review timeline.
At the time of this announcement, BMY was trading at $66.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $136.8B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.